LEGOS, université Paris-Dauphine, place Maréchal-de-Lattre-de-Tassigny, 75116 Paris, France.
Service d'endocrinologie, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France.
Ann Endocrinol (Paris). 2021 Apr;82(2):99-106. doi: 10.1016/j.ando.2020.12.009. Epub 2021 Jan 5.
Different countries have their own systems for evaluating new medicines, and they make decisions as to when and how each new medicine is adopted.
To compare the rate of uptake of new diabetes medicines (dipeptidyl peptidase-4 inhibitors [DPP-4Is], glucagon-like peptide-1 receptor agonists [GLP1-RAs], and sodium-glucose co-transporter-2 inhibitors [SGLT2Is]) in the five most populated European countries.
The monthly volume of sales of antidiabetic drugs was extracted for each country from the IQVIA™ MIDAS® database for the period 2007 to 2016 and the defined daily doses (DDDs) were calculated. For each new drug, market shares were expressed as a percentage of the total market of non-insulin antidiabetic agents.
Sharp differences were observed between the countries. Overall, the highest and fastest rates of uptake were seen for Germany and Spain, compared to lower rates for the UK and Italy. This was especially marked for DPP-4Is, where the market share reached over 30% of non-insulin antidiabetic drugs in Germany and Spain, compared to around 10% in the UK and Italy. In France, there was an initial rapid uptake, which stabilized at around 20% after three years. Rates of uptake were lower for the other drugs, with the GLP1-RAs reaching a market share of 2.5-4.5% in Germany, Spain and France, compared to less than 2.5% in the UK and Italy. The SGLT2Is reached a market share of 5-8% in Spain and Germany, compared to less than 4% in the UK and Italy, and they were not launched at all in France in March 2020.
The differences in the uptake of new antidiabetic drugs may reflect different methods for assessing and introducing new medicines, as well as cultural factors. The uptake of the new medicines would appear to be more cautious in the UK and Italy, perhaps due to concerns about cost-effectiveness, whereas in Germany and Spain, and possibly also France, a new medicine's potential benefits may be prioritized.
不同国家有自己的新药评估体系，它们会决定何时以及如何采用每种新药。
比较五个欧洲人口最多的国家新型糖尿病药物（二肽基肽酶-4 抑制剂[DPP-4Is]、胰高血糖素样肽-1 受体激动剂[GLP1-RAs]和钠-葡萄糖共转运蛋白 2 抑制剂[SGLT2Is]）的采用速度。
从 IQVIA™ MIDAS®数据库中提取 2007 年至 2016 年期间每个国家的抗糖尿病药物月销售量，并计算出定义日剂量（DDD）。对于每种新药，市场份额以其在非胰岛素抗糖尿病药物总市场中的百分比表示。
各国之间存在明显差异。总体而言，德国和西班牙的采用速度最快，采用率最高，而英国和意大利的采用率较低。DPP-4Is 的情况尤其明显，在德国和西班牙，其市场份额达到了非胰岛素抗糖尿病药物的 30%以上，而在英国和意大利，这一比例约为 10%。在法国，最初的采用速度很快，但在三年后稳定在 20%左右。其他药物的采用率较低，GLP1-RAs 在德国、西班牙和法国的市场份额达到 2.5-4.5%，而在英国和意大利则不到 2.5%。SGLT2Is 在西班牙和德国的市场份额达到 5-8%，而在英国和意大利则不到 4%，并且在 2020 年 3 月法国根本没有推出这些药物。
新型抗糖尿病药物采用率的差异可能反映了不同的新药评估和引入方法以及文化因素。在英国和意大利，新型药物的采用似乎更为谨慎，这可能是由于对成本效益的担忧，而在德国、西班牙，可能还有法国，新药的潜在益处可能被优先考虑。
Zotero 插件